Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study-Reference-Cited by-同舟云学术

Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study

Published:2023-12-29 Issue: Volume: Page:
ISSN:0937-4477
Container-title:European Archives of Oto-Rhino-Laryngology
language:en
Short-container-title:Eur Arch Otorhinolaryngol

Author:

De Corso Eugenio^ORCID,Montuori Claudio^ORCID,Baroni Silvia,Mastrapasqua Rodolfo F.,Porru Davide P.,D’Auria Leandro M.^ORCID,D’Agostino Giuseppe^ORCID,Penazzi Daniele,De Maio Gabriele,Onori Maria E.,Sarlo Francesca,Corbo’ Marco,Galli Jacopo^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Otorhinolaryngology

Link

https://link.springer.com/content/pdf/10.1007/s00405-023-08417-8.pdf

Reference46 articles.

1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl 29):1–464. https://doi.org/10.4193/Rhin20.600

2. Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P et al (2023) EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 61(3):194–202. https://doi.org/10.4193/Rhin22.489

3. De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L et al (2022) Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital 42(1):1–16. https://doi.org/10.14639/0392-100X-N1614

4. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P et al (2016) Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA 315(5):469

5. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. The Lancet 394(10209):1638–1650. https://doi.org/10.1001/jama.2015.19330

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps;Nutrients;2024-09-04

2. Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up;Rhinology Journal;2024-06-01